MicroStrategy
MSTR
Adobe
ADBE
Salesforce
CRM
Apple
AAPL
Meritage Homes
MTH
US Stock MarketDetailed Quotes
ALLR Allarity Therapeutics
- 0.9901
- -0.0399-3.87%
Close Dec 20 16:00 ET
- 1.0097
- +0.0196+1.98%
Post 20:01 ET
4.39MMarket Cap-0.14P/E (TTM)
1.0200High0.9100Low551.12KVolume1.0000Open1.0300Pre Close545.47KTurnover12.43%Turnover Ratio0.00P/E (Static)4.43MShares342.000052wk High0.34P/B4.39MFloat Cap0.900052wk Low--Dividend TTM4.43MShs Float15288000.0000Historical High--Div YieldTTM10.68%Amplitude0.9000Historical Low0.9890Avg Price1Lot Size
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Allarity Therapeutics Stock Forum
📊⚡️📊
👀
Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements
Allarity Therapeutics (NASDAQ: ALLR) reported significant progress in its Phase 2 stenoparib trial for advanced ovarian cancer, with two patients exceeding 14 months of treatment.
The company maintains a strong financial position with $18.5 million cash balance as of September 30, 2024, enabling advancement toward FDA approval. Additionally, Allarit...
👀
No comment yet